Quince Therapeutics, Inc. (QNCX) · Oct 19, 2026 · Other events

IRulya updates corporate presentation; LAM-001 milestones largely known

No new info

IRulya’s new corporate presentation recaps LAM-001’s pulmonary pipeline and trial milestones, but adds little beyond information already disclosed.

IRulya is now a pulmonary-focused clinical biotech building LAM-001, a once-daily inhaled rapamycin treatment across PH-ILD, BOS, and SAPH. Its Phase 2a PH study is complete, the BOS study is ongoing, PH-ILD development is advancing, and a SAPH study is expected in late 2026.

This 8-K is a communications refresh, not a new operating event. The filing says the company posted an updated corporate presentation dated October 2026.

The deck mainly repackages the existing clinical story and milestone calendar. The Phase 2a signals, ongoing BOS trial, PH-ILD Phase 2b program, and planned SAPH study were already disclosed in the company’s prior business updates and investor materials. The presentation reiterates that the BOS trial is fully enrolled with data anticipated in the first quarter of 2027.

There is no new efficacy readout, financing, regulatory decision, or changed guidance here. The presentation continues to frame LAM-001’s small open-label Phase 2a dataset as supportive, but the filing does not add blinded trial results or remove the clinical and funding risks already attached to the program.

Bottom line: This filing keeps IRulya’s renamed pulmonary-development story visible but does not materially change it. The next genuinely informative event is the BOS Phase 2 data expected in the first quarter of 2027.

What to watch next

BOS Phase 2 data, Q1 2027

Original filing on SEC EDGAR

IRulya updates corporate presentation; LAM-001 milestones largely known | QNCX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.